Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Moxifloxacin versus high-dose penicillin therapy for community-acquired pneumonia
2005-000771-18Phase 3Completed
- Sponsor
- University Hospital Ulm
- Start
- May 2006
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of moxifloxacin, amoxicillin and ampicillin in community-acquired pneumonia (CAP) (2 arms), sponsored by University Hospital Ulm. Primary endpoints: Clinical cure at end of therapy and Clinical cure after at least 7 days. Started May 2006; status: completed.
02
Drugs
moxifloxacinamoxicillinampicillin
03
Conditions
community-acquired pneumonia (CAP)
Beyond the preview
Go deeper on 2005-000771-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000771-18.